World Journal of Surgical Oncology (Jan 2019)

Spontaneous regression of transverse colon cancer with high-frequency microsatellite instability: a case report and literature review

  • Nozomi Karakuchi,
  • Manabu Shimomura,
  • Kazuhiro Toyota,
  • Takao Hinoi,
  • Hideki Yamamoto,
  • Seiji Sadamoto,
  • Koichi Mandai,
  • Hiroyuki Egi,
  • Hideki Ohdan,
  • Tadateru Takahashi

DOI
https://doi.org/10.1186/s12957-018-1552-x
Journal volume & issue
Vol. 17, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background Spontaneous regression (SR) of colorectal cancer (CRC) is extremely rare, and only few cases have been reported. Although it is not yet clarified, a plausible mechanism for SR of CRC is an immunological event. Case presentation In this report, we present the case of SR of primary CRC in a 78-year-old man. Preoperative colonoscopy was performed, and a type 2 tumor measuring 30 mm in diameter in the transverse colon was detected. The biopsy revealed a poorly differentiated adenocarcinoma. Colectomy was performed 2 months after initial colonoscopy. During the surgery, only a 10-mm ulcer harboring a polypoid lesion measuring 8.5 mm was detected in the resected tissue; no other masses or carcinoma cells were seen on histological examination. Afterwards, the biopsy specimens were reanalyzed, and immunohistological analysis verified this as adenocarcinoma with stroma-infiltrating lymphocytes. Further analysis revealed a loss of two mismatch repair proteins, suggesting sporadic high-frequency microsatellite instability (MSI-H). Conclusion According to previous literature, a common site of SR in CRC is the proximal colon, which is a feature of MSI-H CRC. However, our report showed a rare case of SR of CRC, which was in the transverse colon, with MSI-H present. This report indicates a relationship between immunological features of MSI-H and the occurrence of SR of CRC. A better understanding of this phenomenon and the mechanisms involved will have significant preventive and therapeutic implications for CRC, including anti-PD-1 immune checkpoint inhibitor therapy.

Keywords